PERBEDAAN ANTARA EKSPRESI CD3, CD20, CD43 LIMFOMA NON-HODGKIN SEL B DAN LESI LIMFOPROLIFERATIF REAKTIF
DOI:
https://doi.org/10.21776/ub.majalahkesehatan.2019.006.04.3Keywords:
CD3, CD20, CD43, Lesi limfoproliferatif reaktif, Limfoma non-Hodgkin sel BAbstract
Lesi limfoproliferatif sering menimbulkan masalah dalam penegakan diagnosis karena kemiripan morfologi dan pola pertumbuhan sel-sel limfoid yang menyusun lesi limfoproliferatif reaktif dan limfoma non-Hodgkin Sel B. Diagnosis sulit ditegakkan hanya dengan pulasan rutin Hematoksilin-Eosin, oleh karena itu diperlukan pemeriksaan imunohistokimia menggunakan panel antibodi yang tepat. Penelitian ini bertujuan untuk mengetahui perbedaan ekspresi CD3, CD20, CD43 sebagai panel antibodi dasar dalam menentukan karakter jinak atau ganas dari lesi limfoproliferatif. Karakter jinak diwakili oleh lesi limfoproliferatif reaktif, sedangkan karakter ganas diwakili oleh limfoma non-Hodgkin sel B. Total 50 sampel dibagi menjadi 2Â kelompok, yakni kelompok A terdiri dari 25 sampel limfoma non-Hodgkin sel B dan kelompok B terdiri dari 25 sampel lesi limfoproliferatif reaktif. Keseluruhan sampel dipulas antibodi CD3, CD20, CD43. Hasil penelitian menunjukkan persentase imunopositif CD3 dan CD20 pada kelompok A dan B berbeda signifikan dengan nilai p < 0,001. Hal ini menunjukkan bahwa CD3 dan CD20 mampu membedakan karakter klonalitas jinak dan ganas dari sel penyusun lesi limfoproliferatif. Persentase imunopositif CD43 antara kelompok A dan B tidak berbeda signifikan dengan nilai p = 0,791. Hasil yang tidak berbeda signifikan mengindikasikan bahwa CD43 diekspresikan oleh dua jenis populasi sel yang berbeda. Pada kelompok A, CD43 diekspresikan oleh limfosit B neoplastik (ganas), sedangkan pada kelompok B diekspresikan oleh limfosit T. Berdasarkan hasil penelitian, panel antibodi CD3, CD20, CD43 dapat membedakan lesi limfoproliferatif jinak dan ganas, namun diperlukan korelasi morfologi dan kesesuaian pola ekspresi imunopositif dari sel-sel limfoid penyusunnya.
Â
Â
Â
References
Bégueret H, Vergier B, Parrens M, Lehours P, Laurent F, Vernejoux J-M, et al. Primary Lung Small B-Cell Lymphoma Versus Lymphoid Hyperplasia: Evaluation of Diagnostic Criteria in 26 Cases. The American Journal of Surgical Pathology. 2002; 26(1):76-81.
Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective Immunophenotyping for Diagnosis of B-Cell Neoplasms: Immunohistochemistry and Flow Cytometry Strategies and Results. Applied Immunohistochemistry & Molecular Morphology: AIMM/Official Publication of the Society for Applied Immunohistochemistry. 2013; 21(2):116.
Weiss LM, O'malley D. Benign Lymphadenopathies. Modern Pathology. 2013; 26(S1):S88.
Jaffe ES CE, Harris NL, Pileri SA, Stein H, Swerdlow SHs. Introduction and Overview of the Classification of Lymphoid Neoplasm. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon, France: International Agency for Research on Cancer (IARC). 2017. p. 192-6.
Disanto MG, Ambrosio MR, Rocca BJ, Ibrahim HA, Leoncini L, Naresh KN. Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries with Limited Resources and for Triaging Cases before Referral to Specialist Centers. American Journal of Clinical Pathology. 2016; 145(5):687-95.
Zhang X, Aguilera N. New Immunohistochemistry for B-Cell Lymphoma and Hodgkin Lymphoma. Archives of Pathology & Laboratory Medicine. 2014;v138(12):1666-72.
Castellarin P, Pozzato G, Tirelli G, Di Lenarda R, Biasotto M. Oral Lesions and Lymphoproliferative Disorders. Journal of Oncology. 2010; 2010: 202305.
Kim H-J, Ko YH, Kim JE, Lee S-S, Lee H, Park G, et al. Epstein-Barr Virus–Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification. Journal of Pathology and Translational Medicine. 2017; 51(4):352.
Dong HY, Gorczyca W, Liu Z, Tsang P, Wu CD, Cohen P, et al. B-Cell Lymphomas with Coexpression of CD5 and CD10. American Journal of Clinical Pathology. 2003;119(2):218-30.
Higgins RA, Blankenship JE, Kinney MC. Application of Immunohistochemistry in the Diagnosis of Non-Hodgkin and Hodgkin Lymphoma. Archives of Pathology & Laboratory Medicine. 2008; 132(3):441-61.
Garcia CF, Swerdlow SH. Best Practices in Contemporary Diagnostic Immunohistochemistry: Panel Approach to Hematolymphoid Proliferations. Archives of Pathology & Laboratory Medicine. 2009; 133(5):756-65.
Wang H-Y, Zu Y. Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry. Archives of Pathology & Laboratory Medicine. 2017; 141(9):1236-46.
Das DK. Contribution of Immunocytochemistry to the Diagnosis of Usual and Unusual Lymphoma Cases. Journal of Cytology. 2018; 35(3):163.
De Tute R. A Review of Flow Cytometry and its Use in the Diagnosis and Management of Mature Lymphoid Malignancies. 2011; 58(1):2-12.
Horvat M, Kloboves Prevodnik V, Lavrencak J, Jezersek Novakovic B. Predictive Significance of the Cut-Off Value of CD20 Expression in Patients with B-Cell Lymphoma. Oncology reports. 2010; 24(4):1101-7.
Kennedy GA, Cull G, Gill D, Marlton P, Norris D, Cobcraft R. Identification of Tumours with the CD43 Only Phenotype During the Investigation of Suspected Lymphoma: a Heterogeneous Group not Necessarily of T Cell Origin. Pathology. 2002; 34(1):46-50.
Mitrovic Z, Iqbal J, Fu K, Smith LM, Bast M, Greiner TC, et al. CD 43 Expression is Associated with Inferior Survival in the Nonâ€Germinal Centre Bâ€Cell Subgroup of Diffuse Large Bâ€Cell Lymphoma. British Journal of Haematology. 2013; 162(1):87-92.
Bacon CM, Du M-Q, Dogan A. Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: a Practical Guide for Pathologists. Journal of Clinical Pathology. 2007; 60(4):361-72.
Lai R, Weiss LM, Chang KL, Arber DA. Frequency of CD43 Expression in Non-Hodgkin Lymphoma: a Survey of 742 Cases and Further Characterization of Rare CD43+ Follicular Lymphomas. American Journal of Clinical Pathology. 1999; 111(4):488-94.
Lee P-S, Beneck D, Weisberger J, Gorczyca W. Coexpression of CD43 by Benign B Cells in the Terminal Ileum. Applied Immunohistochemistry & Molecular Morphology. Appl Immunohistochem Mol Morphol. 2005; 13(2):138-41.
Rawal A, Finn WG, Schnitzer B, Valdez R. Site-Specific Morphologic Differences in Extranodal Marginal Zone B-cell Lymphomas. Archives of Pathology & Laboratory Medicine. 2007; 131(11):1673-8.
Ma Xb, Zhong Yp, Zheng Y, Jiang J, Wang Yp. Coexpression of CD 5 and CD 43 Predicts Worse Prognosis in Diffuse Large Bâ€Cell Lymphoma. Cancer Medicine. 2018; 7(9):4284-95.
